106 related articles for article (PubMed ID: 20198594)
21. Prospective study of coffee consumption and risk of Parkinson's disease.
Sääksjärvi K; Knekt P; Rissanen H; Laaksonen MA; Reunanen A; Männistö S
Eur J Clin Nutr; 2008 Jul; 62(7):908-15. PubMed ID: 17522612
[TBL] [Abstract][Full Text] [Related]
22. Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and non-motor symptoms.
Prediger RD
J Alzheimers Dis; 2010; 20 Suppl 1():S205-20. PubMed ID: 20182024
[TBL] [Abstract][Full Text] [Related]
23. Teratogen update: evaluation of the reproductive and developmental risks of caffeine.
Christian MS; Brent RL
Teratology; 2001 Jul; 64(1):51-78. PubMed ID: 11410911
[TBL] [Abstract][Full Text] [Related]
24. Antagonism of haloperidol-induced swim impairment in L-dopa and caffeine treated mice: a pre-clinical model to study Parkinson's disease.
Luthra PM; Barodia SK; Raghubir R
J Neurosci Methods; 2009 Apr; 178(2):284-90. PubMed ID: 19146880
[TBL] [Abstract][Full Text] [Related]
25. Adenosine receptor blockade reverses hypophagia and enhances locomotor activity of dopamine-deficient mice.
Kim DS; Palmiter RD
Proc Natl Acad Sci U S A; 2003 Feb; 100(3):1346-51. PubMed ID: 12538862
[TBL] [Abstract][Full Text] [Related]
26. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
[TBL] [Abstract][Full Text] [Related]
27. Chronic caffeine consumption prevents cognitive decline from young to middle age in rats, and is associated with increased length, branching, and spine density of basal dendrites in CA1 hippocampal neurons.
Vila-Luna S; Cabrera-Isidoro S; Vila-Luna L; Juárez-Díaz I; Bata-García JL; Alvarez-Cervera FJ; Zapata-Vázquez RE; Arankowsky-Sandoval G; Heredia-López F; Flores G; Góngora-Alfaro JL
Neuroscience; 2012 Jan; 202():384-95. PubMed ID: 22155266
[TBL] [Abstract][Full Text] [Related]
28. Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats.
Rojo AI; Cavada C; de Sagarra MR; Cuadrado A
Exp Neurol; 2007 Nov; 208(1):120-6. PubMed ID: 17880941
[TBL] [Abstract][Full Text] [Related]
29. Tobacco, coffee, and Parkinson's disease.
Gale C; Martyn C
BMJ; 2003 Mar; 326(7389):561-2. PubMed ID: 12637374
[No Abstract] [Full Text] [Related]
30. Protective effects of Chunghyuldan against ROS-mediated neuronal cell death in models of Parkinson's disease.
Kim HG; Ju MS; Kim DH; Hong J; Cho SH; Cho KH; Park W; Lee EH; Kim SY; Oh MS
Basic Clin Pharmacol Toxicol; 2010 Dec; 107(6):958-64. PubMed ID: 20629656
[TBL] [Abstract][Full Text] [Related]
31. Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
Pérez V; Sosti V; Rubio A; Barbanoj M; Rodríguez-Alvarez J; Kulisevsky J
Eur J Pharmacol; 2007 Dec; 576(1-3):83-90. PubMed ID: 17888901
[TBL] [Abstract][Full Text] [Related]
32. Controversies on new animal models of Parkinson's disease pro and con: the rotenone model of Parkinson's disease (PD).
Schmidt WJ; Alam M
J Neural Transm Suppl; 2006; (70):273-6. PubMed ID: 17017541
[TBL] [Abstract][Full Text] [Related]
33. Molecular hydrogen is protective against 6-hydroxydopamine-induced nigrostriatal degeneration in a rat model of Parkinson's disease.
Fu Y; Ito M; Fujita Y; Ito M; Ichihara M; Masuda A; Suzuki Y; Maesawa S; Kajita Y; Hirayama M; Ohsawa I; Ohta S; Ohno K
Neurosci Lett; 2009 Apr; 453(2):81-5. PubMed ID: 19356598
[TBL] [Abstract][Full Text] [Related]
34. Chronic but not acute treatment with caffeine attenuates traumatic brain injury in the mouse cortical impact model.
Li W; Dai S; An J; Li P; Chen X; Xiong R; Liu P; Wang H; Zhao Y; Zhu M; Liu X; Zhu P; Chen JF; Zhou Y
Neuroscience; 2008 Feb; 151(4):1198-207. PubMed ID: 18207647
[TBL] [Abstract][Full Text] [Related]
35. The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Burns RS; LeWitt PA; Ebert MH; Pakkenberg H; Kopin IJ
N Engl J Med; 1985 May; 312(22):1418-21. PubMed ID: 2581135
[TBL] [Abstract][Full Text] [Related]
36. Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes.
Bishnoi M; Chopra K; Kulkarni SK
Eur J Pharmacol; 2006 Dec; 552(1-3):55-66. PubMed ID: 17064683
[TBL] [Abstract][Full Text] [Related]
37. Association between caffeine intake and risk of Parkinson's disease among fast and slow metabolizers.
Tan EK; Chua E; Fook-Chong SM; Teo YY; Yuen Y; Tan L; Zhao Y
Pharmacogenet Genomics; 2007 Nov; 17(11):1001-5. PubMed ID: 18075470
[TBL] [Abstract][Full Text] [Related]
38. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease.
Liu B; Dluzen DE
Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):555-65. PubMed ID: 17581209
[TBL] [Abstract][Full Text] [Related]
39. [Experimental models of Parkinson's disease].
Féger J; Pessigliore M; François C; Tremblay L; Hirsch E
Ann Pharm Fr; 2002 Jan; 60(1):3-21. PubMed ID: 11976545
[TBL] [Abstract][Full Text] [Related]
40. Trichloroethylene: Parkinsonism and complex 1 mitochondrial neurotoxicity.
Gash DM; Rutland K; Hudson NL; Sullivan PG; Bing G; Cass WA; Pandya JD; Liu M; Choi DY; Hunter RL; Gerhardt GA; Smith CD; Slevin JT; Prince TS
Ann Neurol; 2008 Feb; 63(2):184-92. PubMed ID: 18157908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
